Multicentric prospective study for therapy of erectile dysfunction after nerve sparing radical prostatectomy: sildenafil (50 mg daily dosing) versus intracorporeal injection of alprostadil (10 microg 3/week).

Trial Profile

Multicentric prospective study for therapy of erectile dysfunction after nerve sparing radical prostatectomy: sildenafil (50 mg daily dosing) versus intracorporeal injection of alprostadil (10 microg 3/week).

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 19 Oct 2011

At a glance

  • Drugs Alprostadil; Sildenafil
  • Indications Erectile dysfunction
  • Focus Therapeutic Use
  • Acronyms TEDAP
  • Sponsors Pfizer
  • Most Recent Events

    • 19 Oct 2011 Status changed from completed to discontinued as reported by ISRCTN: Current Controlled Trials record..
    • 01 Nov 2009 Actual end date (Mar 2007) added as reported by ISRCTN: Current Controlled Trials record.
    • 21 Apr 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top